OncoMatch/Clinical Trials/NCT03647358
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Is NCT03647358 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including PET/CT Scan and Iodine-124 for thyroid carcinoma.
Treatment: PET/CT Scan · Iodine-124 — The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: total thyroidectomy
Adult thyroid carcinoma patients who have undergone total thyroidectomy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify